cyc 202 has been researched along with dinaciclib in 14 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (dinaciclib) | Trials (dinaciclib) | Recent Studies (post-2010) (dinaciclib) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 133 | 12 | 129 |
| Protein | Taxonomy | cyc 202 (IC50) | dinaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0272 | |
| Cyclin-K | Homo sapiens (human) | 0.0227 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0162 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0742 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.049 | |
| Cyclin-A2 | Homo sapiens (human) | 0.002 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.119 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.0028 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0074 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.23 | |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | 0.0039 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.414 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.324 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.1273 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0227 | |
| Cyclin-H | Homo sapiens (human) | 0.17 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.17 | |
| Cyclin-A1 | Homo sapiens (human) | 0.003 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.011 | |
| Heat shock factor protein 1 | Homo sapiens (human) | 0.007 | |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.0219 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 0.0323 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 8 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Baltus, CB; Bazgier, V; Berka, K; Jorda, R; Kryštof, V; Marot, C; Prié, G; Viaud-Massuard, MC | 1 |
| Havlíček, L; Jorda, R; Kryštof, V; Pospíšil, T; Skrášková, Z; Strnad, M; Šturc, A; Vymětalová, L | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Marzaro, G; Poratti, M | 1 |
| Cui, S; Galons, H; Huang, Y; Ingarra, AM; Li, T; Lu, K; Oumata, N; Teng, Y; Yu, P; Zhang, Q; Zhao, L | 1 |
| Bian, J; Li, Z; Qin, Z; Tian, Y; Wang, J; Wu, T; Xu, C | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Chen, K; Jiang, H; Li, J; Li, Y; Lin, T; Liu, L; Luo, C; Xu, P; Zhou, B | 1 |
| George, RF; Georgey, HH; Hassan, GS; Mahmoud, WR; Mohammed, EZ; Omar, FA | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
| Giordano, A; Morales, F | 1 |
| Burban, D; Faber, EB; Georg, GI; Hawkinson, JE; Levinson, NM; Tian, D | 1 |
| Antony, T; Gore, S; Krishnamurthy, NR; More, SS; Nataraj, V; Pothuganti, M; Ramachandra, M; Talapati, SR | 1 |
6 review(s) available for cyc 202 and dinaciclib
| Article | Year |
|---|---|
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Topics: Aminopyridines; Benzimidazoles; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Humans; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Structure-Activity Relationship | 2019 |
Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Development; Humans; Protein Kinase Inhibitors; Pyrimidines; Triazines | 2019 |
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary | 2020 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |
Overview of CDK9 as a target in cancer research.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Flavonoids; Humans; Indolizines; Molecular Targeted Therapy; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridinium Compounds; Roscovitine; Thiazoles; Urea | 2016 |
8 other study(ies) available for cyc 202 and dinaciclib
| Article | Year |
|---|---|
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Heterocyclic Compounds; Humans; Indoles; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship | 2016 |
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; G2 Phase; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Structure-Activity Relationship | 2021 |
Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quantitative Structure-Activity Relationship | 2021 |
Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.
Topics: Allosteric Regulation; Anilino Naphthalenesulfonates; Cyclic N-Oxides; Cyclin-Dependent Kinase 2; Drug Synergism; Humans; Indolizines; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Pyridinium Compounds; Roscovitine | 2020 |
Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Topics: A549 Cells; Adenosine Triphosphate; Antineoplastic Agents; Binding Sites; Cell Proliferation; Cloning, Molecular; Crystallography, X-Ray; Cyclic N-Oxides; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Escherichia coli; Gene Expression; Genetic Vectors; Humans; Indolizines; Models, Molecular; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Purines; Pyridinium Compounds; Recombinant Proteins; Roscovitine | 2020 |